Xiaoqing Xu

Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression.

Jingming Zhang, T-G Huang, K. Xie, 2021, International immunopharmacology.

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

T-G Huang, K. Xie, Yan Feng, 2022, Cancers.

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

Yan Feng, Jingming Zhang, K. Xie, 2022, Life.

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

K. Xie, Yan Feng, Jian-min Fang, 2022, Journal for ImmunoTherapy of Cancer.

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody

Ruiqin Wang, K. Xie, Jianmin Fang, 2020, Drug design, development and therapy.

Genetic analysis of heterogeneous sub-clones in recombinant Chinese hamster ovary cells

Dong Li, Cizhong Jiang, Lingxia Jiang, 2017, Applied Microbiology and Biotechnology.

Improved recombinant protein production by regulation of transcription and protein transport in Chinese hamster ovary cells

Dong Li, Cizhong Jiang, Ruiqin Wang, 2019, Biotechnology Letters.

Improved recombinant protein production by regulation of transcription and protein transport in Chinese hamster ovary cells

Dong Li, Cizhong Jiang, Jianmin Fang, 2019, Biotechnology Letters.